Oral antispastic drugs in nonprogressive neurologic diseases: A systematic review

Neurology

Volumn 63, Issue 8, 2004, Pages 1357-1363

  Montané, Eva ^a,b,c,d   Vallano, A ^b,c,d   Laporte, J R ^a,b,c,d  

^a U d'Assaigs Clin/Farmacoepidemiol   (Spain)

^b Fundacion Institut Catala de Farmacologia   (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BACLOFEN; DANTROLENE; DIAZEPAM; GABAPENTIN; SPASMOLYTIC AGENT; TIZANIDINE;

CEREBRAL PALSY; CLINICAL TRIAL; COCHRANE LIBRARY; DROWSINESS; DRUG ACTIVITY; DRUG EFFICACY; HUMAN; MEDLINE; META ANALYSIS; METHODOLOGY; MUSCLE WEAKNESS; NEUROLOGIC DISEASE; NONPROGRESSIVE NEUROLOGIC DISEASE; OUTCOMES RESEARCH; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SEDATION; SIDE EFFECT; SPASTICITY; SPINAL CORD DISEASE; STROKE; SYSTEMATIC REVIEW;

EID: 7044237006     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000141863.52691.44     Document Type: Review

References (33)

1. Young RR. Spasticity: a review. Neurology 1994;44(suppl 9):12-20.
2. The management of spasticity. Drug Ther Bull 2000;38:6.
3. Kita M, Goodkin DE. Drugs used to treat spasticity. Drugs 2000;59:487-495.
4. Shakespeare DT, Boggild M, Young C. Anti-spasticity agents for multiple sclerosis. The Cochrane Library, Issue 4, 2000.
5. Paisley S, Beard S, Hunn A, Wight J. Clinical effectiveness of oral treatments for spasticity in multiple sclerosis: a systematic review. Mult Scler 2002;8:319-329.
6. Groves L, Shellenberger MK, Davis CS. Tizanidine treatment of spasticity: a meta-analysis of controlled, double-blind, comparative studies with baclofen and diazepam. Adv Ther 1998;15:241-251.
7. Wallace JD. Summary of combined clinical analysis of controlled clinical trials with tizanidine. Neurology 1994;44(suppl 9):60-69.
8. Lataste X, Emre M, Davis C, Groves L. Comparative profile of tizanidine in the management of spasticity. Neurology 1994;44(suppl 9):53-59.
9. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Controlled Clin Trials 1996;17:1-12.
10. Ashworth B. Preliminary trial of carisoprodol in multiple sclerosis. Practitioner 1964;192:540-542.
11. Milla PJ, Jackson ADM. A controlled trial of baclofen in children with cerebral palsy. J Int Med Res 1977;5:398-404.
12. Haslam RHA, Walcher JR, Lietman PS, Kallman CH, Mellits ED. Dantrolene sodium in children with spasticity. Arch Phys Med Rehabil 1974;55:384-388.
13. Joynt RL, Leonard JA. Dantrolene sodium suspension in treatment of spastic cerebral palsy. Dev Med Child Neurol 1980;22:755-767.
14. Nance PW, Bugaresti J, Shellenberger K, Sheremata W, Martinez-Arizala A, and the North American Tizanidine Study Group. Efficacy and safety of tizanidine in the treatment of spasticity in patients with spinal cord injury. Neurology 1994;44(suppl 9):44-52.
15. Corbett M, Frankel HL, Michaelis L. A double blind, cross-over trial of Valium in the treatment of spasticity. Paraplegia 1972;10:19-22.
16. Gruenthal M, Mueller M, Olson WL, Priebe MM, Sherwood AM, Olson WH. Gabapentin for the treatment of spasticity in patients with spinal cord injury. Spinal Cord 1997;35:686-689.
17. Bes A, Eyssette M, Pierrot-Deseilligny E, Rohmer F, Warter JM. A multi-centre, double-blind trial of tizanidine, a new antispastic agent, in spasticity associated with hemiplegia. Curr Med Res Opin 1988;10:709-718.
18. Medici M, Pebet M, Ciblis D. A double-blind, long-term study of tizanidine ("Sirdalud") in spasticity due to cerebrovascular lesions. Curr Med Res Opin 1989;11:398-407.
19. Ketel WB, Kolb ME. Long-term treatment with dantrolene sodium of stroke patients with spasticity limiting the return of function. Curr Med Res Opin 1984;9:161-169.
20. Medaer R, Hellebuyk H, Van Den Brande E, et al. Treatment of spasticity due to stroke. A double-blind, cross-over trial comparing baclofen with placebo. Acta Therapeutica 1991;17:323-331.
21. Meythaler JM, Guin-Renfroe S, Johnson A, Brunner RM. Prospective assessment of tizanidine for spasticity due to acquired brain injury. Arch Phys Med Rehabil 2001;82:1155-1163.
22. Katrak PH, Cole AMD, Poulos CJ, McCauley JCK. Objective assessment of spasticity, strength, and function with early exhibition of dantrolene sodium after cerebrovascular accident: a randomised doubleblind controlled study. Arch Phys Med Rehabil 1992;73:4-9.
23. Petticrew M. Why certain systematic reviews reach uncertain conclusions. BMJ 2003;326:756-758.
24. Abbruzzese G. The medical management of spasticity. Eur J Neurol 2002;9(suppl 1):30-34.
25. Dietz V. Spastic movement disorder: what is the impact of research on clinical practice? J Neurol Neurosurg Psychiatry 2003;74:820-821. Letter.
26. Wagstaff AJ, Bryson HM. Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders. Drugs 1997;53:435-452.
27. Rode G, Maupas E, Luaute J, Courtois-Jacquin S, Boisson D. Traitements médicamenteux de la spasticité. Neurochirurgie 2003;49:247-255.
28. Dickersin K, Chan S, Chalmers TC, Sacks HS, Smith H Jr. Publication bias and clinical trials. Control Clin Trials 1987;8:343-353.
29. Taricco M, Adone R, Pagliacci C, Telaro E. Pharmacological interventions for spasticity following spinal cord injury (Cochrane Review). The Cochrane Library, Issue 4, 2000.
30. Ade-Hall RA, Moore AP. Botulinum toxin type A in the treatment of lower limb spasticity in cerebral palsy (Cochrane Review). The Cochrane Library, Issue 4, 2000.
31. Sweetman SC. Martindale: the complete drugs reference, 33rd ed. London: Pharmaceutical Press, 2002;1322-1330.
32. Killestein J, Uitdehaag BMJ, Polman CH. Cannabinoids in multiple sclerosis: do they have a therapeutic role? Drugs 2004;64:1-11.
33. Ward AB. A summary of spasticity management-a treatment algorithm. Eur J Neurol 2002;9(suppl 1):48-52.